Reproducibility of three 6-min walk tests in patients with COPD referred for pulmonary rehabilitation

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2025-01-01 DOI:10.1016/j.rmed.2024.107884
Jeannet M. Delbressine , Anouk W. Vaes , Wieteke A.M. Stoop , Dirk Van Ranst , Martijn A. Spruit , Alex van ’t Hul
{"title":"Reproducibility of three 6-min walk tests in patients with COPD referred for pulmonary rehabilitation","authors":"Jeannet M. Delbressine ,&nbsp;Anouk W. Vaes ,&nbsp;Wieteke A.M. Stoop ,&nbsp;Dirk Van Ranst ,&nbsp;Martijn A. Spruit ,&nbsp;Alex van ’t Hul","doi":"10.1016/j.rmed.2024.107884","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The 6-min walk test (6MWT) is used to assess functional capacity in patients with COPD. A significant number of studies have shown that most patients walk further in a second 6MWT. Research on a further increase in the 6-min walk distance (6MWD) during a 3rd test performed in accordance with current guidelines has not been done. Therefore, this study aimed to investigate 1) the reproducibility of three 6MWTs in patients with COPD referred for pulmonary rehabilitation (PR) and 2) predictors of improvement on a third 6MWT.</div></div><div><h3>Materials and methods</h3><div>Before the start of PR, 1167 COPD patients (50 % male, age: 62 ± 9 years; FEV1: 42 ± 18%pred) performed three 6MWTs (6MWT1, 6MWT2, and 6MWT3). A predetermined threshold of ≥42m improvement in 6MWD in consecutive 6MWT's was used to identify improvers. Reproducibility between tests was assessed using a Bland-Altman plot and logistic regression analyses were performed to assess effects of sex, age, body mass index, GOLD-stage, 6MWD, use of supplemental oxygen and use of walking aids.</div></div><div><h3>Results</h3><div>Generally, the 6MWD improved (6MWT1: 343 ± 115m; 6MWT2: 367 ± 115m; 6MWT3: 381 ± 116m). 210 patients (18 %) improved ≥42m from 6MWT2 to 6MWT3. The Bland-Altman plot showed that the 95 % limits of agreement of 6MWT3 vs 6MWT2 exceeded 42m, indicating that 6MWT2 is not reproducible. Predictors of improvement in 6MWT3 were GOLD stage I/II and a low 6MWD (&lt;350m) in the previous two 6MWTs.</div></div><div><h3>Conclusions</h3><div>These results indicate that three 6MWTs may be required to obtain the largest pre-PR functional capacity in COPD patients. Patients with a 6MWD &lt;350m and GOLD-stage I/II are more likely to improve ≥42m in a third 6MWT.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"236 ","pages":"Article 107884"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124003597","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives

The 6-min walk test (6MWT) is used to assess functional capacity in patients with COPD. A significant number of studies have shown that most patients walk further in a second 6MWT. Research on a further increase in the 6-min walk distance (6MWD) during a 3rd test performed in accordance with current guidelines has not been done. Therefore, this study aimed to investigate 1) the reproducibility of three 6MWTs in patients with COPD referred for pulmonary rehabilitation (PR) and 2) predictors of improvement on a third 6MWT.

Materials and methods

Before the start of PR, 1167 COPD patients (50 % male, age: 62 ± 9 years; FEV1: 42 ± 18%pred) performed three 6MWTs (6MWT1, 6MWT2, and 6MWT3). A predetermined threshold of ≥42m improvement in 6MWD in consecutive 6MWT's was used to identify improvers. Reproducibility between tests was assessed using a Bland-Altman plot and logistic regression analyses were performed to assess effects of sex, age, body mass index, GOLD-stage, 6MWD, use of supplemental oxygen and use of walking aids.

Results

Generally, the 6MWD improved (6MWT1: 343 ± 115m; 6MWT2: 367 ± 115m; 6MWT3: 381 ± 116m). 210 patients (18 %) improved ≥42m from 6MWT2 to 6MWT3. The Bland-Altman plot showed that the 95 % limits of agreement of 6MWT3 vs 6MWT2 exceeded 42m, indicating that 6MWT2 is not reproducible. Predictors of improvement in 6MWT3 were GOLD stage I/II and a low 6MWD (<350m) in the previous two 6MWTs.

Conclusions

These results indicate that three 6MWTs may be required to obtain the largest pre-PR functional capacity in COPD patients. Patients with a 6MWD <350m and GOLD-stage I/II are more likely to improve ≥42m in a third 6MWT.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三种六分钟步行试验在COPD患者转介肺部康复中的可重复性
介绍和目的:6分钟步行试验(6MWT)用于评估COPD患者的功能能力。大量研究表明,大多数患者在第二个6MWT中走得更远。在按照现行指南进行的第三次测试中,关于进一步增加6分钟步行距离(6MWD)的研究尚未完成。因此,本研究旨在探讨1)三种6MWT在COPD患者肺康复(PR)中的可重复性,以及2)第三种6MWT改善的预测因素。材料与方法:PR开始前,1167例COPD患者(50%男性,年龄:62±9岁;FEV1: 42±18%pred)分别进行6MWT1、6MWT2和6MWT3三组6MWTs。采用连续6MWT的6MWD改善≥42m的预定阈值来识别改善者。采用Bland-Altman图评估试验之间的可重复性,并进行logistic回归分析以评估性别、年龄、体重指数、gold分期、6MWD、使用补充氧和使用助行器的影响。结果:6MWD总体改善(6MWT1: 343±115m;6 mwt2: 367±115米;6 mwt3: 381±116米)。210例(18%)患者从6MWT2到6MWT3改善≥42m。Bland-Altman图显示6MWT3与6MWT2的95%一致性限超过42m,表明6MWT2不可重复。6MWT3改善的预测因子是GOLD期I/II期和低6MWD(结论:这些结果表明,COPD患者可能需要3个6MWTs才能获得最大的pr前功能容量。6MWD患者
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
期刊最新文献
Home noninvasive ventilation in pediatric patients: Does one size fit all? Diagnostic and prognostic implications of a deep suprasternal notch in idiopathic pleuroparenchymal fibroelastosis Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids? Investigating the risk factors for the coexistence of insomnia and its exacerbation in AECOPD Exploring the Effects of Pulmonary Rehabilitation and its Determinants in Lung Transplant Candidates with Cystic Fibrosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1